Anti-MUC1, Recombinant [SM3]
Invented by Prof Joyce Taylor-Papadimitriou at Absolute Antibody Cancer Research UK London Research Institute: Lincoln's Inn Fields
Catalogue Number | 151161 |
Applications | ELISA FACS IHC |
Antigen/Gene or Protein Targets | Mucin1 (MUC1) |
Synonyms | ADMCKD, ADMCKD1, Breast carcinoma associated antigen DF3, Breast carcinoma-associated antigen DF3, CA 15-3, CA15 3, CA15 3 antigen, CA15.3, Cancer antigen 15-3, Carcinoma associated mucin, Carcinoma-associated mucin, CD 227, CD227 |
Reactivity | Human |
Relevance | MUC1 is a large cell surface mucin glycoprotein expressed by most glandular and ductal epithelial cells and some hematopoitic cell lineages. In the vast majority of human carcinomas, this protein is upregulated, poorly glycosylated and appears on the cell surface in a non-polarised fashion. SM3 antibody recognises this under-glycosylated form of MUC1 and is therefore tunour specific and may be relevant for breast cancer therapy. SM3 also detects MUC1 within colon and ovarian cancer and most adenocarcinomas and may be used for immunohistochemistry (reactive with methacarn fixed tissue), and immunotargeting. |
Host | Mouse |
Immunogen | Hydrogen fluoride deglycosylated milk mucin. |
Positive Control | MCF7 cells (FACS) or human breast carcinoma (IHC) |
Subclass | IgG2a kappa |
Myeloma Used | P3X63Ag8.653 |
Recommended Growing Conditions | RPMI 1640 + 10% FCS |
Strain | Balb/c |
Notes | The product of the MUC1 gene is the polymorphic epithelial mucin. SM3 reacts with a core protein epitope defined as PDTRP. |
Research Area | Cancer, Cell Type or Organelle Marker, Cell Signaling & Signal Transduction |
Geng et al. 2013. Cell Mol Bioeng. 6(2):148-159. PMID: 23805168.
Targeting Underglycosylated MUC1 for the Selective Capture of Highly Metastatic Breast Cancer Cells Under Flow.
Europe PMC ID: 23805168
Sørensen et al. 2006. Glycobiology. 16(2):96-107. PMID: 16207894.
Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Europe PMC ID: 16207894
Brockhausen et al. 1995. Eur J Biochem. 233(2):607-17. PMID: 7588808.
Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells.
Europe PMC ID: 7588808
Burchell et al. 1993. Epithelial Cell Biol. 2(4):155-62. PMID: 7505698.
FACS
Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product.
Europe PMC ID: 7505698
Burchell et al. 1989. Int J Cancer. 44(4):691-6. PMID: 2477336.
A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.
Europe PMC ID: 2477336
Burchell et al. 1987. Cancer Res. 47(20):5476-82. PMID: 2443241.
Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin.
Europe PMC ID: 2443241
Geng et al. 2013. Cell Mol Bioeng. 6(2):148-159. PMID: 23805168.
Targeting Underglycosylated MUC1 for the Selective Capture of Highly Metastatic Breast Cancer Cells Under Flow.
Sørensen et al. 2006. Glycobiology. 16(2):96-107. PMID: 16207894.
Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Brockhausen et al. 1995. Eur J Biochem. 233(2):607-17. PMID: 7588808.
Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells.
Burchell et al. 1993. Epithelial Cell Biol. 2(4):155-62. PMID: 7505698.
FACS
Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product.
Burchell et al. 1989. Int J Cancer. 44(4):691-6. PMID: 2477336.
A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.
Burchell et al. 1987. Cancer Res. 47(20):5476-82. PMID: 2443241.
Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin.